The Role of Gut Microbiota-derived Short Chain Fatty Acids in Amyotrophic Lateral Sclerosis

Purpose of ReviewThe purpose of this review is to explore the critical role of short-chain fatty acids (SCFAs) in the regulation of various physiological functions and their implications in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). By examining the metabolic, endocrine, and immune functions influenced by SCFAs such as acetate, propionate, and butyrate this review aims to elucidate the mechanisms through which these metabolites contribute to gut-brain communication and the progression of ALS.Recent FindingsRecent investigations have highlighted the significance of SCFAs in the context of ALS, revealing their potential as mediators that can modulate disease progression and cognitive decline. SCFAs have been shown to influence key metabolic pathways linked to ALS pathogenesis, demonstrating both pro-inflammatory and anti-inflammatory properties that modulate the inflammatory landscape of the central nervous system. Additionally, SCFAs exert a protective effect against oxidative stress, which is a crucial factor in ALS deterioration. Furthermore, alterations in intestinal microbiota composition have been observed in ALS patients, indicating that SCFAs may also play a role in the gut-microbiota-brain axis, thereby influencing the overall progression of the disease.SummarySCFAs represent a promising avenue for understanding the complex interplay between gut health and neurodegenerative diseases like Amyotrophic Lateral Sclerosis. The dual effects of SCFAs ranging from their regulatory influence on metabolic pathways to their modulation of inflammatory responses and oxidative stress underscore their potential therapeutic significance. Further research into the interactions between SCFAs and intestinal microbiota composition may reveal novel insights into their role in ALS pathogenesis and the development of targeted interventions for this debilitating condition.